Medscape December 16, 2024
Deena Beasley

(Reuters) – Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with obesity-related conditions or take the drugs to become eligible for other services, health records and discussions with doctors show.

An exclusive analysis of hundreds of thousands of electronic patient records by health data firm Truveta found slight, but measurable, increases in first-time diagnoses of sleep apnea, cardiovascular disease, and type 2 diabetes within 15 days of an initial prescription for a GLP-1 weight-loss drug between 2020 and 2024.

In addition to obesity-related conditions, some patients are being prescribed the drugs to lose weight and become eligible for services including organ transplants, fertility treatments or knee replacements, according to interviews with seven...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Physician, Provider
National Health Expenditures In 2023: Faster Growth As Insurance Coverage And Utilization Increased
Startup SiteOne Secures $100M to Forge Ahead With Novel Non-Opioid Pain Meds
Health care package winners and losers
A New Weight Loss Drug With No Side Effects? Yes…So Far
The AI Advantage: Reimagining the Future of Drug Development

Share This Article